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1. Introduction 
After the discovery of the enkephalin [ 11, it was 
reported [2] that the order of potency for morphine 
and the enkephalins was inversed in the mouse vas 
deferens (in comparison with the guinea pig ileum), 
thus suggesting the existence of various class of opiate 
receptors. However, a major problem in the precise 
characterization of the different receptors has been 
the absence of very selective ligands for one peculiar 
subclass of opiate receptors. In [3] morphiceptin, the 
amide of a fragment of the milk protein fl-casein, was 
suggested to represent a highly selective ligand for the 
p opiate receptor. In [4] the enkephalin analogue, 
Tyr-D-Ser- Gly-Phe-Leu-Thr was proposed as a 
selective ligand for the 6 opiate receptor. Synthesis of 
various enkephalin analogues with potent activity in 
the guinea pig ileum bioassay as well as significant 
analgesic activity after subcutaneous administration 
was reported in [5-71. One of these analogues, Tyr- 
D-Met-Gly-MePheol, named ‘syndyphalin (SD)25’ 
was 23 300-times and g-times as active as morphine 
in the guinea pig ileum bioassay and in the tail flick 
analgesic test after subcutaneous administration, 
respectively [7]. Here, we report the potency of this 
analogue on the p, 6 and K opiate receptors using 
[ 3H] dihydromorphine (DHM), D- [ 3H] Ala’,DLeu’- 
enkephalin (DADLEU) and [ 3H] ethylketocyclazocine 
(EKC) as their respective ligands. Our results show 
that SD-25 is a highly specific and selective ligand for 
the /J opiate receptor. 
2. Materials and methods 
Binding experiments were performed using frozen 
slide-mounted brain sections as in [8] for [ 3H]DHM 
and [3H]DADLEU and as in [9,10] for [3H]EKC. 
Briefly, male Sprague-Dawley rats (- 200 g body wt) 
were sacrificed by decapitation. Their brains were 
rapidly excised, quick-frozen in isopentane at -40°C 
and mounted on cryostat chucks. The cortex was 
carefully shaved off down to the level of the corpus 
callosum, and 25 p-thick coronal sections of caudate- 
putamen at midstriatal levels were cut at -14°C. 
Sections were thaw-mounted near the edge of cleaned 
gelatin-coated slides, air-dried on ice for - 2 h, and 
then dried at -14“C for at least 48 h before use. Slide 
mounted sections (1 section/slide) were incubated in 
30 ml beakers in 10 ml as follows: for [ 3H] DHM, in a 
50 mM Tris-HCl buffer containing 3 mM Mn (OAc),, 
1% BSA, 1 nM [3H]DHM (6.5 Ci/mmol; Amersham) 
at pH 7.4,25”C for 30 min with various concentra- 
tions of SD25, morphiceptin (Peninsula) or other 
opiates; for [ 3H] DADLEU, in a 50 mM Tris-HCl 
buffer containing 100 mM NaCl, 3 mM Mn (OAc),, 
2 PM GTP, 1% BSA, 2.5 nM [3H] DADLEU (25 Ci/ 
mmol; Amersham) at pH 7.4, 25°C for 30 min with 
various concentrations of SD-25, morphiceptin or 
other opiates; for [ 3H]EKC, in a 50 mM K2HP0, . 
HCl buffer containing 1 mM EDTA, 100 mM NaCl, 
2.3 nM [ 3H] EKC (15 Ci/mmol; New England Nuclear) 
at pH 7.4,4”C for 60 min with various concentrations 
of SD-25, morphiceptin or other opiates. At the end 
of the incubation, the slides were placed in racks 
holding 30 slides and transferred sequentially through 
6 rinses (20 s in each) of incubation buffer without 
salt (pH 7.4) at 4°C plus 1% BSA. Binding of [jH]- 
labeled ligands to the tissue slice was quantitated by 
counting the tissue-laden slide fragment in 10 ml 
Aquassure scintillation cocktail (New England Nuclear) 
after vigorously agitating the vial contents for 30 min. 
Specific binding was calculated as the difference in 
counts bound in the presence and absence of 1 PM 
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etorphine for [ 3H] DHM and L3H] DADLEU and 
10 PM ECK for [ 3H] EKC. Synthesis of syndyphalin 
(SD)25 was described in [7]. 
3. Results and discussion 
SD-25 is more potent than morphine itself in dis- 
placing [ 3H] DHM binding, a prototype /.I opiate recep- 
tor ligand (fig.1). SD-25 appears to possess muchmore 
affinity for this site than morphiceptin. In fact, SD-25 
is probably the most potent peptide or peptide anal- 
ogue on /A opiate binding site [ 111. 
The high selectivity of SD-25 is very interesting. 
SD-25 is a very weak displacer of t3H]DADLEU and 
[ 3H] EKC, respectively prototypes of the 6 and K 
opiate binding sites (fig.2,3). These results indicate 
that SD-25 is a very selective ligand for the P opiate 
binding, being at least as selective as morphiceptin 
(table 1) [3]. Subsequent studies using SD-25 as a 
highly selective ligand may reveal more precisely the 
structural requirement of this opiate receptor subtype. 
Moreover, conformational analysis of this peptide 
analogue should help to design an even more selective 
ligand . 
Based on our binding assay data, the potency of 
SD-25 in the guinea pig ileum would have been 
[IH]-DIHYDR~M~RPHINE 
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Fig.1. Displacement of [ 3H] DHM by SD-25, morphiceptin 
and morphine. Slide-mounted caudate sections were incubated 
with 1 .O nM [ 3H] DHM and increasing amounts of the various 
opiates under study. Non-specific binding in presence of 
1.0 MM etorphine has been subtracted from all experimental 
points. Values are expressed as percentage inhibition of spe- 
cific binding of [SH]DHM and are shown as log-probit plots. 
The experiment has been replicated 3-times and varied <15%. 
expected to be lower than found (table 1) [7], sug- 
gesting that the great potency of SD-25 in this bio- 
assay is not only related to an increased affinity for 
the binding site, but also to other factors such as an 
increased resistance to enzymatic degradation. The 
greater analgesic potency of SD-25 compared to mor- 
[‘HID-Ala2,D-Let+ENKEPHALIN 
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Fig.2. Displacement of [“HIDADLEU by SD-25, morphiceptin and DADLEU. Slidemounted caudate sections were incubated 
with 2.5 nM [‘HIDADLEU and increasing amounts of the various opiates under study. Non-specific binding in presence of 
1.0 yM etorphine has been subtracted from all experimental points. Values are expressed as percentage inhibition of specific bind- 
ing of [3H]DADLEU and are shown as log-probit plots. The experiment has been replicated 3-times and varied <15%. 
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[+I]-ETHYLKETOCYCIAZOCINE 
Fig.3. Displacement of [ ‘H]EKC by SD-25, morphiceptin and EKC. Slide-mounted caudate sections were incubated with 2.3 nM 
[“H]EKC and increasing amounts of the various opiates under study. Non-specific binding in presence of 10 nM EKC has been 
subtracted from all experimental points. Values are expressed as percentage inhibition of specific binding of [‘HI EKC ad are 
shown as log-probit plots. The experiments has been replicated 3-times and varied <20%. 
phine (table 1) [7] might be due to a combination of 
these factors namely the high affinity for the ~1 opiate 
binding site, an easier crossing of the blood-brain 
barrier, and the resistance to enzymatic degradation. 
Our results also support the hypothesis that cc opiate 
receptors mediate the analgesic effects of opiates [ 121, 
since SD25 is a potent analgesic devoided of affinity 
for 6 and K opiate receptors. Finally, the very high 
analgesic effect of SD-25 after subcutaneous adminis- 
tration may indicate that the development of a long- 
lasting, orally effective opiate peptide analgesic might 
be expected in the near future. 
Table 1 
Potency of syndyphalin SD-25 and morphiceptin on various binding sites and in some biological systems 
Compound [ 3H]DHM 
lc,oa (nM) 
[3H]DADLEU 
IC*, WI 
[sH]EKC 
IC,, W) 
Guinea pig ileum 
ED,,b 0.M) 
Analgesic effect 
Tail flick writhing 
ED,,’ (mg/kg, s.c.1 
Syndyphalin 
SD25 0.29 0.05 1250 200 13 000 3000 0.0025 0.0009c 0.54c 0.1sc 
Morphiceptin 10.0 1.6 19 500 3000 21000 4000 130d - - 
Morphine 0.78 0.1 - - 52.4 6.3’ 2.55’ 0.5oc 
DADLEU - 3.4 0.6 _ - _ 
EKC - 2.4 0.5 - - - 
a IC,, is the concentration which inhibits the binding of the labeled ligand by 50%; values represent mean + SEM of 3 deter- 
minations, each in triplicate 
b ED,, is the concentration which suppresses the electrically stimulated muscle contraction by 50% or the dose which induces 
analgesia in 50% of the animals 
c Data from [ 71 
d Data from [ 31 
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